Pharming PHAR
NASDAQ PHAR
$13.40 +0.38 (+2.92%)
As of: Nov 11, 2026 · 3:17 PM EST

Pharming (PHAR) Net Income Attributable to Noncontrolling Interests (2025)

Updated

Pharming (PHAR) recorded Net Income Attributable to Noncontrolling Interests of -$313,000 in FY2025.

Analysis

Pharming (PHAR) Net Income Attributable to Noncontrolling Interests (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCI Net Income (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 2.00 Mn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 2.00 Mn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -1.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 10.00 Mn
10 Pharming 927.62 Mn 229.29 Mn 102.20 -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 169,000.00
Jun 30, 2025 -313,000.00
Mar 31, 2025 -169,000.00
API Access

Pharming Net Income Attributable to Noncontrolling Interests API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=PHAR&period=max&api_key=YOUR_API_KEY